Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 13
Submit an article Journal homepage
422
Views
10
CrossRef citations to date
0
Altmetric
Letters to the Editor

Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience

Elisabetta Antoniolia Haematology Unit, Careggi University Hospital, Florence, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5547-3516
ORCID Icon,
Michela Staderinia Haematology Unit, Careggi University Hospital, Florence, Italy
,
Sofia Pilercia Haematology Unit, Careggi University Hospital, Florence, Italy
,
Federico Perfettob Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy
,
Francesco Cappellib Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy
,
Marco Allinovib Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy;c Nephrology, Dialysis and Transplantation Unit, Careggi Hospital, Firenze, Italy
,
Chiara Nozzolid Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy
,
Irene Attuccia Haematology Unit, Careggi University Hospital, Florence, Italy
,
Alessandra Buzzichellia Haematology Unit, Careggi University Hospital, Florence, Italy
,
Maria Messeria Haematology Unit, Careggi University Hospital, Florence, Italy
&
Alberto Bosia Haematology Unit, Careggi University Hospital, Florence, Italy
 show all
Pages 3255-3258 | Received 06 May 2020, Accepted 15 Jul 2020, Published online: 10 Aug 2020

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Rafael Ríos-Tamayo, Juan Alfons Soler, Ricarda García-Sánchez, Ernesto Pérez Persona, Mario Arnao, Antoni García-Guiñón, Abel Domingo, Miriam González-Pardo, Javier de la Rubia & María Victoria Mateos. (2023) A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study. Hematology 28:1.
Read now
Ashutosh D. Wechalekar, M. Teresa Cibeira, Simon D. Gibbs, Arnaud Jaccard, Shaji Kumar, Giampaolo Merlini, Giovanni Palladini, Vaishali Sanchorawala, Stefan Schönland, Christopher Venner, Mario Boccadoro & Efstathios Kastritis. (2023) Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid 30:1, pages 3-17.
Read now

Articles from other publishers (8)

Manlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, Alessandro Allegra, Uroš Markovic, Cirino Botta, Fabrizio Accardi, Iolanda Donatella Vincelli, Salvatore Leotta, Federica Elia, Benedetta Esposito, Bruno Garibaldi, Gabriele Sapuppo, Alessandra Orofino, Alessandra Romano, Giuseppe A. Palumbo, Francesco Di Raimondo & Concetta Conticello. (2023) Multiple Myeloma in 2023 Ways: From Trials to Real Life. Current Oncology 30:11, pages 9710-9733.
Crossref
Martin Stork, Ivan Spicka, Jakub Radocha, Jiri Minarik, Tomas Jelinek, Alexandra Jungova, Petr Pavlicek, Lenka Pospisilova, Frantisek Sedlak, Jan Straub, Tomas Pika, Zdenka Knechtova, Anna Fidrichova, Ivanna Boichuk, Sabina Sevcikova, Vladimir Maisnar, Roman Hajek & Ludek Pour. (2023) Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis. Annals of Hematology 102:6, pages 1501-1511.
Crossref
Ling-Jung Chiu, Chin-Yuan Kuo, Ming-Chun Ma, Chun-Kai Liao, Hung-Lin Liu & Ming-Chung Wang. (2023) Real-world evidence of daratumumab-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: A single-center experience in Taiwan focusing on efficacy. Journal of Cancer Research and Practice 10:1, pages 19.
Crossref
Silvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, Sara Pezzatti, Angelo Belotti, Francesca Fazio, Roberto Mina, Magda Marcatti, Anna Cafro, Renato Zambello, Laura Paris, Gregorio Barilà, Cecilia Olivares, Alessandra Pompa, Rita Mazza, Francesca Farina, Martina Soldarini, Pietro Benvenuti, Giuseppina Pagani, Michele Palumbo, Valeria Masoni, Virginia Valeria Ferretti, Catherine Klersy, Luca Arcaini & Maria Teresa Petrucci. (2022) Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis. Haematologica 108:3, pages 833-842.
Crossref
G. Mele, N. Cascavilla, N. Di Renzo, A. Guarini, P. Mazza, L. Melillo, V. Pavone, G. Tarantini, P. Curci, A. P. Falcone, C. Germano, A. Mele, G. Palazzo, G. Palumbo, G. Reddiconto, B. Rossini, G. Specchia, P. Musto & D. Pastore. (2022) Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by ‘Rete Ematologica Pugliese’. Annals of Hematology 101:8, pages 1727-1739.
Crossref
Francesca Fazio, Luca Franceschini, Valeria Tomarchio, Angela Rago, Maria Grazia Garzia, Luca Cupelli, Velia Bongarzoni, Alessandro Andriani, Svitlana Gumenyuk, Agostino Tafuri, Agostina Siniscalchi, Alfonso Piciocchi, Paolo De Fabritiis, Luca De Rosa, Tommaso Caravita di Toritto, Ombretta Annibali, Maria Cantonetti & Maria Teresa Petrucci. (2022) Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group. eJHaem 3:1, pages 121-128.
Crossref
Ludovica Fucci, Lorenzo Gensini, Ugo Coppetelli, Elettra Ortu La Barbera, Martina Gentile, Luciano Fiori, Salvatore Perrone & Giuseppe Cimino. (2022) Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience. Leukemia Research Reports 17, pages 100330.
Crossref
. (2021) Multiple drugs. Reactions Weekly 1841:1, pages 187-187.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.